Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva's Slow Recovery Proceeds With Flat Revenue Forecast In 2021

Feb 10 2021

• By Jessica Merrill

New winding road in the mountain — Teva's return to growth has been winding • Source: Shutterstock

Related Content

As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes

Feb 05 2021

Teva Edges Closer To Growth, But With A Big Overhang

Feb 12 2020

Related Companies

Teva Pharmaceutical Industries Ltd.

Gilead Sciences, Inc.

Merck & Co., Inc.

Roche Holding AG

Additional Topics

Generic Drugs Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window